Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the ...
Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...
New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...